Immix Biopharma, Inc. vs Immuneering Corporation — Valuation Comparison 2026
Access all valuation models for IMMX vs IMRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →IMMX scores higher with a 5.1/10 quality rating vs IMRX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Immix Biopharma, Inc. (IMMX) and Immuneering Corporation (IMRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
IMMX currently trades at $8.84 with a QOC of 5.1/10, while IMRX trades at $5.06 with a QOC of 4.5/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).